Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bach Thanh¹,Galbiati Shirley²,Kennedy Jessie K.²,Deye Gregory³,Nomicos Effie Y. H.³,Codd Ellen E.⁴⁵,Garcia Hector H.⁵⁶,Horton John⁵⁷,Gilman Robert H.⁵⁸,Gonzalez Armando E.⁵⁶⁹,Winokur Patricia¹⁰,An Guohua¹^ORCID

Affiliation:

1. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA

2. The Emmes Company, Rockville, Maryland, USA

3. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA

4. Codd Consulting, LLC, Blue Bell, Pennsylvania, USA

5. Oxfendazole Development Group, Blue Bell, Pennsylvania, USA

6. Center for Global Health, Universidad Peruana Cayetano Heredia, Lima, Peru

7. Tropical Projects, Hitchin, United Kingdom

8. Johns Hopkins School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

9. School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru

10. Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

Abstract

Neurocysticercosis and trichuriasis are difficult-to-treat parasitic infections that affect more than 1.5 billion people worldwide. Oxfendazole, a potent broad-spectrum benzimidazole anthelmintic approved for use in veterinary medicine, has shown substantial antiparasitic activity against neurocysticercosis and intestinal helminths in preclinical studies. As part of a program to transition oxfendazole from veterinary medicine to human use, phase I multiple ascending dose and food effect studies were conducted.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01018-20

Reference39 articles.

1. WHO. 2017. Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases. WHO Geneva Switzerland.

2. WHO. 2012. Eliminating soil-transmitted helminthiases as a public health problem in children: progress report 2001–2010 and strategic plan 2011–2020. WHO Geneva Switzerland.

3. WHO. 2018. Soil transmitted helminth infections. https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections. Accessed 30 December 2019.

4. Efficacy of Current Drugs Against Soil-Transmitted Helminth Infections

5. A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis;Trends in Parasitology;2024-09

2. An insight into the Success, Challenges, and Future perspectives of eliminating Neglected tropical disease;Scientific African;2024-06

3. Combinations of the azaquinazoline anti-Wolbachia agent, AWZ1066S, with benzimidazole anthelmintics synergise to mediate sub-seven-day sterilising and curative efficacies in experimental models of filariasis;Frontiers in Microbiology;2024-02-01

4. Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in Gambia;Pharmaceutics;2024-01-31

5. Understanding the pathogenic mechanisms and therapeutic effects in neurocysticercosis;Brain Pathology;2024-01-11